The Gastric Cancer chapter of the NCCN Drugs and Biologics Compendium™ now includes a recommendation for trastuzumab to be used in combination with systemic chemotherapy for the treatment of patients with advanced gastric cancer that is HER-2 positive as determined by a standardized method.
Van Cutsem, et. al. presented data from a phase III trial of 594 patients with HER-2 positive advanced gastric cancer at ASCO in June 2009. Patients were randomized to receive chemotherapy with or without trastuzumab. Overall survival in patients randomized to receive trastuzumab with chemotherapy was significantly (13.8 vs 11.1 months, p=0.0048) greater than with chemotherapy alone. Secondary efficacy parameters were also significantly improved.
This NCCN recommendation is based on deliberations of the NCCN Clinical Practice Guidelines in Oncology™ Gastric Cancer Panel. The recommendation is a Category 2A Recommendation according to the NCCN categories of evidence and consensus.